_id
6919f5dc3c536f8df2318766
Ticker
NP5.XETRA
Name
NEWRON PHARMACEUT. EO-20
Exchange
XETRA
Address
Via Antonio Meucci 3, Bresso, MI, Italy, 20091
Country
Germany
Sector
Healthcare
Industry
Biotechnology
Currency
EUR
Website
https://www.newron.com
Description
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Last Close
26.1
Volume
2482
Current Price
32.9
Change
0.9578544061302682
Last Updated
2025-12-30T12:17:02.012Z
Image
https://logo.clearbit.com/www.newron.com
Ipo Date
-
Market Cap
520981952
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
11898000
Cost Of Revenue
-
Gross Profit
11898000
Operating Expenses
10553000
Operating Income
1345000
Interest Expense
2244799
Pretax Income
-57000
Net Income
-73000
Eps
-0.003657314629258517
Dividends Per Share
-
Shares Outstanding
19960994
Income Tax Expense
16000
EBITDA
1430000
Operating Margin
11.304420911077493
Total Other Income Expense Net
-1402000
Cash
26639000
Short Term Investments
16556000
Receivables
8240000
Inventories
-
Total Current Assets
60468000
Property Plant Equipment
780000
Total Assets
61394000
Payables
1090000
Short Term Debt
33897000
Long Term Debt
18055000
Total Liabilities
59812000
Equity
1582000
Bs_currency_symbol
EUR
Depreciation
85000
Change In Working Capital
35801000
Cash From Operations
33604491
Capital Expenditures
31000
Cash From Investing
-13655193
Cash From Financing
-94708
Net Change In Cash
26639000
Cf_currency_symbol
-
PE
19.1912
PB
415.0973451327433
ROE
-4.61441213653603
ROA
-0.11890412743916343
FCF
33573491
Fcf Percent
2.8217760127752562
Piotroski FScore
2
Health Score
28
Deep Value Investing Score
4
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
5.8
Garp Investing Score
2.5
Growth Investing Score
3
Momentum Investing Score
7
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
3.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
11898000
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
11898000
Quarters > 0 > income Statement > operating Expenses
10553000
Quarters > 0 > income Statement > operating Income
1345000
Quarters > 0 > income Statement > interest Expense
2244799
Quarters > 0 > income Statement > pretax Income
-57000
Quarters > 0 > income Statement > net Income
-73000
Quarters > 0 > income Statement > eps
-0.003657314629258517
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
19960000
Quarters > 0 > income Statement > income Tax Expense
16000
Quarters > 0 > income Statement > EBITDA
1430000
Quarters > 0 > income Statement > operating Margin
11.304420911077493
Quarters > 0 > income Statement > total Other Income Expense Net
-1402000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
26639000
Quarters > 0 > balance Sheet > short Term Investments
16556000
Quarters > 0 > balance Sheet > receivables
8240000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
60468000
Quarters > 0 > balance Sheet > property Plant Equipment
780000
Quarters > 0 > balance Sheet > total Assets
61394000
Quarters > 0 > balance Sheet > payables
1090000
Quarters > 0 > balance Sheet > short Term Debt
33897000
Quarters > 0 > balance Sheet > long Term Debt
18055000
Quarters > 0 > balance Sheet > total Liabilities
59812000
Quarters > 0 > balance Sheet > equity
1582000
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
-73000
Quarters > 0 > cash Flow > depreciation
85000
Quarters > 0 > cash Flow > change In Working Capital
35801000
Quarters > 0 > cash Flow > cash From Operations
33604491
Quarters > 0 > cash Flow > capital Expenditures
31000
Quarters > 0 > cash Flow > cash From Investing
-13655193
Quarters > 0 > cash Flow > cash From Financing
-94708
Quarters > 0 > cash Flow > net Change In Cash
26639000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.003657314629258517
Quarters > 0 > ratios > PB
415.0973451327433
Quarters > 0 > ratios > ROE
-4.61441213653603
Quarters > 0 > ratios > ROA
-0.11890412743916343
Quarters > 0 > ratios > FCF
33573491
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
2.8217760127752562
Quarters > 0 > health Score
28
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
48168527
Quarters > 1 > income Statement > cost Of Revenue
48168527
Quarters > 1 > income Statement > gross Profit
47983000
Quarters > 1 > income Statement > operating Expenses
14085251
Quarters > 1 > income Statement > operating Income
33986905
Quarters > 1 > income Statement > interest Expense
2166343
Quarters > 1 > income Statement > pretax Income
31057622
Quarters > 1 > income Statement > net Income
25498209
Quarters > 1 > income Statement > eps
1.2775384103870868
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
19958859
Quarters > 1 > income Statement > income Tax Expense
5559412
Quarters > 1 > income Statement > EBITDA
33320342
Quarters > 1 > income Statement > operating Margin
70.5583232802614
Quarters > 1 > income Statement > total Other Income Expense Net
-2929283
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
6933000
Quarters > 1 > balance Sheet > short Term Investments
2893000
Quarters > 1 > balance Sheet > receivables
42423000
Quarters > 1 > balance Sheet > inventories
7917
Quarters > 1 > balance Sheet > total Current Assets
61104000
Quarters > 1 > balance Sheet > property Plant Equipment
832435
Quarters > 1 > balance Sheet > total Assets
63908000
Quarters > 1 > balance Sheet > payables
2465000
Quarters > 1 > balance Sheet > short Term Debt
13553000
Quarters > 1 > balance Sheet > long Term Debt
36243000
Quarters > 1 > balance Sheet > total Liabilities
62450000
Quarters > 1 > balance Sheet > equity
1458000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
25498209
Quarters > 1 > cash Flow > depreciation
96371
Quarters > 1 > cash Flow > change In Working Capital
-36801544
Quarters > 1 > cash Flow > cash From Operations
-8653120
Quarters > 1 > cash Flow > capital Expenditures
5889
Quarters > 1 > cash Flow > cash From Investing
1115472
Quarters > 1 > cash Flow > cash From Financing
6540455
Quarters > 1 > cash Flow > net Change In Cash
-977803
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
1.2775384103870868
Quarters > 1 > ratios > PB
450.3748018518518
Quarters > 1 > ratios > ROE
1748.8483539094648
Quarters > 1 > ratios > ROA
39.89830537647869
Quarters > 1 > ratios > FCF
-8659009
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
-0.17976487011944542
Quarters > 1 > health Score
48
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
3407000
Quarters > 2 > income Statement > cost Of Revenue
95861
Quarters > 2 > income Statement > gross Profit
3407000
Quarters > 2 > income Statement > operating Expenses
11090000
Quarters > 2 > income Statement > operating Income
-7683000
Quarters > 2 > income Statement > interest Expense
2192837
Quarters > 2 > income Statement > pretax Income
-9544000
Quarters > 2 > income Statement > net Income
-9557000
Quarters > 2 > income Statement > eps
-0.5148413510747185
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
18563000
Quarters > 2 > income Statement > income Tax Expense
13000
Quarters > 2 > income Statement > EBITDA
-7587000
Quarters > 2 > income Statement > operating Margin
-225.50631053712942
Quarters > 2 > income Statement > total Other Income Expense Net
-1861000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
7897000
Quarters > 2 > balance Sheet > short Term Investments
4291000
Quarters > 2 > balance Sheet > receivables
2512000
Quarters > 2 > balance Sheet > inventories
-506000
Quarters > 2 > balance Sheet > total Current Assets
20080000
Quarters > 2 > balance Sheet > property Plant Equipment
342000
Quarters > 2 > balance Sheet > total Assets
24937000
Quarters > 2 > balance Sheet > payables
2868000
Quarters > 2 > balance Sheet > short Term Debt
368018
Quarters > 2 > balance Sheet > long Term Debt
48530000
Quarters > 2 > balance Sheet > total Liabilities
55769000
Quarters > 2 > balance Sheet > equity
-30832000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-9557000
Quarters > 2 > cash Flow > depreciation
95861
Quarters > 2 > cash Flow > change In Working Capital
468000
Quarters > 2 > cash Flow > cash From Operations
-8828000
Quarters > 2 > cash Flow > capital Expenditures
7000
Quarters > 2 > cash Flow > cash From Investing
2009000
Quarters > 2 > cash Flow > cash From Financing
8378000
Quarters > 2 > cash Flow > net Change In Cash
1556717
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.5148413510747185
Quarters > 2 > ratios > PB
-19.808079268292683
Quarters > 2 > ratios > ROE
30.99701608718215
Quarters > 2 > ratios > ROA
-38.32457793639973
Quarters > 2 > ratios > FCF
-8835000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-2.5931904901673026
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
3563000
Quarters > 3 > income Statement > cost Of Revenue
102021
Quarters > 3 > income Statement > gross Profit
3563000
Quarters > 3 > income Statement > operating Expenses
10886000
Quarters > 3 > income Statement > operating Income
-7323000
Quarters > 3 > income Statement > interest Expense
2126987
Quarters > 3 > income Statement > pretax Income
-9261000
Quarters > 3 > income Statement > net Income
-9274000
Quarters > 3 > income Statement > eps
-0.519697394228075
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
17845000
Quarters > 3 > income Statement > income Tax Expense
13000
Quarters > 3 > income Statement > EBITDA
-7288000
Quarters > 3 > income Statement > operating Margin
-205.52904855458883
Quarters > 3 > income Statement > total Other Income Expense Net
-1938000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
6338000
Quarters > 3 > balance Sheet > short Term Investments
6261000
Quarters > 3 > balance Sheet > receivables
2022000
Quarters > 3 > balance Sheet > inventories
1
Quarters > 3 > balance Sheet > total Current Assets
19652000
Quarters > 3 > balance Sheet > property Plant Equipment
405000
Quarters > 3 > balance Sheet > total Assets
25866000
Quarters > 3 > balance Sheet > payables
2019000
Quarters > 3 > balance Sheet > short Term Debt
22452000
Quarters > 3 > balance Sheet > long Term Debt
25753000
Quarters > 3 > balance Sheet > total Liabilities
55774000
Quarters > 3 > balance Sheet > equity
-29908000
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
-9274000
Quarters > 3 > cash Flow > depreciation
99000
Quarters > 3 > cash Flow > change In Working Capital
958000
Quarters > 3 > cash Flow > cash From Operations
-4537000
Quarters > 3 > cash Flow > capital Expenditures
3000
Quarters > 3 > cash Flow > cash From Investing
3257000
Quarters > 3 > cash Flow > cash From Financing
-95000
Quarters > 3 > cash Flow > net Change In Cash
-7713000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-0.519697394228075
Quarters > 3 > ratios > PB
-19.63021599572021
Quarters > 3 > ratios > ROE
31.00842583924034
Quarters > 3 > ratios > ROA
-35.854016856104536
Quarters > 3 > ratios > FCF
-4540000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-1.2742071288240246
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
51390000
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
51390000
Annuals > 0 > income Statement > operating Expenses
25217000
Annuals > 0 > income Statement > operating Income
26173000
Annuals > 0 > income Statement > interest Expense
4353000
Annuals > 0 > income Statement > pretax Income
21394000
Annuals > 0 > income Statement > net Income
15843000
Annuals > 0 > income Statement > eps
0.8534719603512363
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
18563000
Annuals > 0 > income Statement > income Tax Expense
5551000
Annuals > 0 > income Statement > EBITDA
25939000
Annuals > 0 > income Statement > operating Margin
50.93014205098269
Annuals > 0 > income Statement > total Other Income Expense Net
-4779000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
6933000
Annuals > 0 > balance Sheet > short Term Investments
2893000
Annuals > 0 > balance Sheet > receivables
42423000
Annuals > 0 > balance Sheet > inventories
7917
Annuals > 0 > balance Sheet > total Current Assets
61104000
Annuals > 0 > balance Sheet > property Plant Equipment
832435
Annuals > 0 > balance Sheet > total Assets
63908000
Annuals > 0 > balance Sheet > payables
2465000
Annuals > 0 > balance Sheet > short Term Debt
13553000
Annuals > 0 > balance Sheet > long Term Debt
36243000
Annuals > 0 > balance Sheet > total Liabilities
62450000
Annuals > 0 > balance Sheet > equity
1458000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
21394000
Annuals > 0 > cash Flow > depreciation
192000
Annuals > 0 > cash Flow > change In Working Capital
-37753000
Annuals > 0 > cash Flow > cash From Operations
-17614000
Annuals > 0 > cash Flow > capital Expenditures
13000
Annuals > 0 > cash Flow > cash From Investing
3158000
Annuals > 0 > cash Flow > cash From Financing
15051000
Annuals > 0 > cash Flow > net Change In Cash
595000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
0.8534719603512363
Annuals > 0 > ratios > PB
339.3031207133059
Annuals > 0 > ratios > ROE
1086.625514403292
Annuals > 0 > ratios > ROA
24.790323590160856
Annuals > 0 > ratios > FCF
-17627000
Annuals > 0 > ratios > Piotroski FScore
2
Annuals > 0 > ratios > fcf Percent
-0.3430044755789064
Annuals > 0 > health Score
48
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
9057000
Annuals > 1 > income Statement > cost Of Revenue
210142
Annuals > 1 > income Statement > gross Profit
9057000
Annuals > 1 > income Statement > operating Expenses
20686000
Annuals > 1 > income Statement > operating Income
-11629000
Annuals > 1 > income Statement > interest Expense
4168000
Annuals > 1 > income Statement > pretax Income
-16200000
Annuals > 1 > income Statement > net Income
-16224000
Annuals > 1 > income Statement > eps
-0.9091622303166152
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
17845000
Annuals > 1 > income Statement > income Tax Expense
24000
Annuals > 1 > income Statement > EBITDA
-11831000
Annuals > 1 > income Statement > operating Margin
-128.3979242574804
Annuals > 1 > income Statement > total Other Income Expense Net
-4571000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
6338000
Annuals > 1 > balance Sheet > short Term Investments
6261000
Annuals > 1 > balance Sheet > receivables
2530000
Annuals > 1 > balance Sheet > inventories
-508001
Annuals > 1 > balance Sheet > total Current Assets
19652000
Annuals > 1 > balance Sheet > property Plant Equipment
405000
Annuals > 1 > balance Sheet > total Assets
25866000
Annuals > 1 > balance Sheet > payables
2019000
Annuals > 1 > balance Sheet > short Term Debt
22452000
Annuals > 1 > balance Sheet > long Term Debt
25753000
Annuals > 1 > balance Sheet > total Liabilities
55774000
Annuals > 1 > balance Sheet > equity
-29908000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-16224000
Annuals > 1 > cash Flow > depreciation
201000
Annuals > 1 > cash Flow > change In Working Capital
1636000
Annuals > 1 > cash Flow > cash From Operations
-10140000
Annuals > 1 > cash Flow > capital Expenditures
11000
Annuals > 1 > cash Flow > cash From Investing
3246000
Annuals > 1 > cash Flow > cash From Financing
-192000
Annuals > 1 > cash Flow > net Change In Cash
-7086000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-0.9091622303166152
Annuals > 1 > ratios > PB
-15.901071619633543
Annuals > 1 > ratios > ROE
54.24635549016985
Annuals > 1 > ratios > ROA
-62.723266063558334
Annuals > 1 > ratios > FCF
-10151000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-1.1207905487468257
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
6094000
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
6094000
Annuals > 2 > income Statement > operating Expenses
19396000
Annuals > 2 > income Statement > operating Income
-13302000
Annuals > 2 > income Statement > interest Expense
4408753
Annuals > 2 > income Statement > pretax Income
-17472000
Annuals > 2 > income Statement > net Income
-17493000
Annuals > 2 > income Statement > eps
-0.9802745867189689
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
17845000
Annuals > 2 > income Statement > income Tax Expense
21000
Annuals > 2 > income Statement > EBITDA
-13323000
Annuals > 2 > income Statement > operating Margin
-218.2802756809977
Annuals > 2 > income Statement > total Other Income Expense Net
-4170000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
13424000
Annuals > 2 > balance Sheet > short Term Investments
9350000
Annuals > 2 > balance Sheet > receivables
1944000
Annuals > 2 > balance Sheet > inventories
1
Annuals > 2 > balance Sheet > total Current Assets
28493000
Annuals > 2 > balance Sheet > property Plant Equipment
527000
Annuals > 2 > balance Sheet > total Assets
37195000
Annuals > 2 > balance Sheet > payables
1909000
Annuals > 2 > balance Sheet > short Term Debt
343605
Annuals > 2 > balance Sheet > long Term Debt
45165000
Annuals > 2 > balance Sheet > total Liabilities
51225000
Annuals > 2 > balance Sheet > equity
-14030000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-17493000
Annuals > 2 > cash Flow > depreciation
202000
Annuals > 2 > cash Flow > change In Working Capital
1911778
Annuals > 2 > cash Flow > cash From Operations
-11092000
Annuals > 2 > cash Flow > capital Expenditures
18000
Annuals > 2 > cash Flow > cash From Investing
-317000
Annuals > 2 > cash Flow > cash From Financing
-186000
Annuals > 2 > cash Flow > net Change In Cash
-11595000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-0.9802745867189689
Annuals > 2 > ratios > PB
-33.8965965787598
Annuals > 2 > ratios > ROE
124.68282252316465
Annuals > 2 > ratios > ROA
-47.030514854147064
Annuals > 2 > ratios > FCF
-11110000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-1.8231046931407942
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
5762000
Annuals > 3 > income Statement > cost Of Revenue
117000
Annuals > 3 > income Statement > gross Profit
5762000
Annuals > 3 > income Statement > operating Expenses
18119000
Annuals > 3 > income Statement > operating Income
-12357000
Annuals > 3 > income Statement > interest Expense
3075244
Annuals > 3 > income Statement > pretax Income
-14884000
Annuals > 3 > income Statement > net Income
-14901000
Annuals > 3 > income Statement > eps
-0.8350238161950126
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
17845000
Annuals > 3 > income Statement > income Tax Expense
17000
Annuals > 3 > income Statement > EBITDA
-12217609
Annuals > 3 > income Statement > operating Margin
-214.4567858382506
Annuals > 3 > income Statement > total Other Income Expense Net
-2527000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
25019000
Annuals > 3 > balance Sheet > short Term Investments
9575000
Annuals > 3 > balance Sheet > receivables
1308000
Annuals > 3 > balance Sheet > inventories
3850
Annuals > 3 > balance Sheet > total Current Assets
39427000
Annuals > 3 > balance Sheet > property Plant Equipment
577000
Annuals > 3 > balance Sheet > total Assets
50486000
Annuals > 3 > balance Sheet > payables
1503000
Annuals > 3 > balance Sheet > short Term Debt
299880
Annuals > 3 > balance Sheet > long Term Debt
42542000
Annuals > 3 > balance Sheet > total Liabilities
47379000
Annuals > 3 > balance Sheet > equity
3107000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-14901000
Annuals > 3 > cash Flow > depreciation
209000
Annuals > 3 > cash Flow > change In Working Capital
-275115
Annuals > 3 > cash Flow > cash From Operations
-11445000
Annuals > 3 > cash Flow > capital Expenditures
20000
Annuals > 3 > cash Flow > cash From Investing
8420000
Annuals > 3 > cash Flow > cash From Financing
14831000
Annuals > 3 > cash Flow > net Change In Cash
11806000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-0.8350238161950126
Annuals > 3 > ratios > PB
153.06380753138075
Annuals > 3 > ratios > ROE
-479.5944641132926
Annuals > 3 > ratios > ROA
-29.515113100661573
Annuals > 3 > ratios > FCF
-11465000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-1.989760499826449
Annuals > 3 > health Score
8
Valuation > metrics > PE
19.1912
Valuation > metrics > PB
415.0973451327433
Valuation > final Score
50
Valuation > verdict
6868.3% Overvalued
Profitability > metrics > ROE
-4.61441213653603
Profitability > metrics > ROA
-0.12072501157637099
Profitability > metrics > Net Margin
-0.006135484955454698
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
37.80783817951959
Risk > metrics > Interest Coverage
0.5991627758209087
Risk > final Score
8
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.7282990825163633
Liquidity > metrics > Quick Ratio
1.7282990825163633
Liquidity > final Score
93
Liquidity > verdict
Great
Prev Valuations > 0
40
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
100
Prev Profitabilities > 1
40
Prev Profitabilities > 2
40
Prev Risks > 0
46
Prev Risks > 1
16
Prev Risks > 2
16
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
50
Updated At
2026-01-20T23:07:24.465Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-12-03
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.12
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
-0.12
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-09-16
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
0
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/APre-market: NP5.DE Newron Pharmaceuticals XETRA -9.85% 14 Jan 2026: catalyst watch Meyka
Read more →Newron presents H1 2025 results and provides business update Business Wire
Read more →(Last Updated 2025-06-30)
Health Score
Price to Earnings Ratio (P/E)
-
High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of NEWRON PHARMACEUT. EO-20
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.12
EPS Estimate
0
EPS Difference
-0.12
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.